Results 21 to 30 of about 43,705 (217)

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Molecular Oncology, 2022
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino   +12 more
doaj   +1 more source

Gemcitabine for relapsed or resistant lymphoma

Annals of Oncology, 2000
Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma.Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment.
D G, Savage, S A, Rule, M, Tighe, T J, Garrett, M W, Oster, R T, Lee, J, Ruiz, D, Heitjan, M L, Keohan, M, Flamm, S A, Johnson   +10 more
openaire   +2 more sources

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. [PDF]

PLoS ONE, 2012
BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E Trujillo, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez   +11 more
doaj   +1 more source

Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

Biomedicines, 2021
Patient-derived xenograft models reportedly represent original tumor morphology and gene mutation profiles. In addition, patient-derived xenografts are expected to recapitulate the parental tumor drug responses.
Erica Yada, Rika Kasajima, Atsushi Niida, Seiya Imoto, Satoru Miyano, Yohei Miyagi, Tetsuro Sasada, Satoshi Wada   +7 more
doaj   +1 more source

Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]

PLoS ONE, 2012
Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong   +6 more
doaj   +1 more source

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Journal of Experimental & Clinical Cancer Research, 2023
Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao, Yabin Yu   +8 more
doaj   +1 more source

Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer

Frontiers in Oncology, 2022
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still remains challenging.
Xinyuan Li, Kai Li, Mengmeng Li, Xiaoyu Lin, Yu Mei, Xuemei Huang, Huanjie Yang   +6 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

APOBEC3 upregulation drives gemcitabine resistance. [PDF]

Nat Cancer
Maciejowski J, Mohamed T.
europepmc   +3 more sources

Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

Cancer Research, 2020
Abstract Pancreatic cancer is characterized by an extensive and complex microenvironment, and is resistant to both chemotherapy and immune checkpoint blockade. The study by Principe and colleagues in this issue of Cancer Research proposes a combinatorial approach based on targeting the very mechanisms of resistance to gemcitabine, a ...
Eileen S. Carpenter, Nina G. Steele, Marina Pasca di Magliano   +2 more
openaire   +2 more sources